Caroline Pettenati1,2, Anne-Sophie Jannot2,3, Sophie Hurel1,2, Virginie Verkarre2,4, Henri Kreis2,5, Martin Housset2,6, Christophe Legendre2,5, Arnaud Méjean1,2, Marc-Olivier Timsit1,2. 1. Department of Urology and Transplant Surgery, Hôpital européen Georges-Pompidou, AP-HP, Paris, France. 2. Université Paris Descartes, Paris, France. 3. Department of Statistics, Computing and Public Health, Hôpital européen Georges-Pompidou, AP-HP, Paris, France. 4. Department of Pathology, Hôpital Necker, AP-HP, Paris, France. 5. Department of Nephrology and Transplantation, Hôpital Necker, AP-HP, Paris, France. 6. Department of Onco-Radiotherapy, Hôpital européen Georges-Pompidou, AP-HP, Paris, France.
Abstract
BACKGROUND: Prostate cancer (PCa) incidence is expected to increase in renal transplant recipients (RTR) with no clear nor contemporary data on management and oncological outcome. METHODS: We conducted a retrospective single center study of RTR diagnosed with PCa after transplantation between 2000 and 2013. Demographics, PCa characteristics, and treatment were assessed. For each RTR in radical prostatectomy (RP) subset, we included 4 non-organ transplant patients who underwent RP by the same surgeons, and compared pre-operative and post-operative oncological features, and biochemical recurrence (BCR) rate. RESULTS: Twenty-four RTR were included (PCa incidence 1.5%). Mean follow-up was 47 months. PCa was mostly localized (n=21, 87.5%) with treatments including RP (n=16, 76.2%), brachytherapy (n=3, 14.3%), radiation therapy (n=1, 4.7%), and active surveillance (n=1, 4.7%). No graft loss due to PCa treatment was reported. Nineteen RTR with localized PCa (90.5%) were free from BCR. Considering RP subset, no difference in PCa characteristics at diagnosis and BCR rate was found between RTR (n=16) and control patients (n=64). CONCLUSIONS: Localized PCa following renal transplantation was not associated with adverse features as compared with non-transplant patients. Standard treatments could be proposed to RTR with satisfying results both on oncological outcome and graft function.
BACKGROUND:Prostate cancer (PCa) incidence is expected to increase in renal transplant recipients (RTR) with no clear nor contemporary data on management and oncological outcome. METHODS: We conducted a retrospective single center study of RTR diagnosed with PCa after transplantation between 2000 and 2013. Demographics, PCa characteristics, and treatment were assessed. For each RTR in radical prostatectomy (RP) subset, we included 4 non-organ transplant patients who underwent RP by the same surgeons, and compared pre-operative and post-operative oncological features, and biochemical recurrence (BCR) rate. RESULTS: Twenty-four RTR were included (PCa incidence 1.5%). Mean follow-up was 47 months. PCa was mostly localized (n=21, 87.5%) with treatments including RP (n=16, 76.2%), brachytherapy (n=3, 14.3%), radiation therapy (n=1, 4.7%), and active surveillance (n=1, 4.7%). No graft loss due to PCa treatment was reported. Nineteen RTR with localized PCa (90.5%) were free from BCR. Considering RP subset, no difference in PCa characteristics at diagnosis and BCR rate was found between RTR (n=16) and control patients (n=64). CONCLUSIONS: Localized PCa following renal transplantation was not associated with adverse features as compared with non-transplant patients. Standard treatments could be proposed to RTR with satisfying results both on oncological outcome and graft function.
Authors: Uwe Bieri; Kerstin Hübel; Harald Seeger; Girish S Kulkarni; Tullio Sulser; Thomas Hermanns; Marian S Wettstein Journal: Clin J Am Soc Nephrol Date: 2020-05-07 Impact factor: 8.237
Authors: Valentina Lancellotta; Andrea D'Aviero; Bruno Fionda; Calogero Casà; Ilaria Esposito; Francesco Preziosi; Anna Acampora; Fabio Marazzi; György Kovács; Barbara Alicja Jereczek-Fossa; Alessio Giuseppe Morganti; Vincenzo Valentini; Maria Antonietta Gambacorta; Jacopo Romagnoli; Luca Tagliaferri Journal: World J Radiol Date: 2022-03-28
Authors: Sung Han Kim; Jae Young Joung; Yoon Seok Suh; Young Ae Kim; Jin Hyuk Hong; Tong Sun Kuark; Eun Sook Lee; Kang Hyun Lee Journal: Oncotarget Date: 2017-07-22